Genentech treatment granted orphan status Genentech's recombinant humanized monoclonal antibody of the immunoglobulin G1 subclass directed against colony stimulating factor-1 receptor expressed on macrophages was granted FDA orphan designation for the treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor, according to a post to the regulator's site. Genentech is wholly owned by Roche Holding. Reference Link
Roche buys nucleic acid purification technology from Lumora Roche has signed a definitive asset purchase agreement with Lumora for products associated with the patent-protected Heat Elution technology for nucleic acid purification of multiple sample types including challenging formalin-fixed paraffin-embedded tumor samples. Roche plans to explore integrating this technology into its sequencing workflow solution.